ES2116801T3 - Empleo de derivados de adamantano para el tratamiento de tinnitus. - Google Patents

Empleo de derivados de adamantano para el tratamiento de tinnitus.

Info

Publication number
ES2116801T3
ES2116801T3 ES96112325T ES96112325T ES2116801T3 ES 2116801 T3 ES2116801 T3 ES 2116801T3 ES 96112325 T ES96112325 T ES 96112325T ES 96112325 T ES96112325 T ES 96112325T ES 2116801 T3 ES2116801 T3 ES 2116801T3
Authority
ES
Spain
Prior art keywords
tinnitus
treatment
adamantane derivatives
alkyl
adamantane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96112325T
Other languages
English (en)
Inventor
Hans Peter Prof Dr Med Zenner
J Peter Prof Dr Ruppersberg
Andreas Dr Busch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TINNITUS FORSCHUNGS und ENTWIC
Original Assignee
TINNITUS FORSCHUNGS und ENTWIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TINNITUS FORSCHUNGS und ENTWIC filed Critical TINNITUS FORSCHUNGS und ENTWIC
Application granted granted Critical
Publication of ES2116801T3 publication Critical patent/ES2116801T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

UTILIZACION DE DERIVADOS DEL ADAMANTANO DE FORMULA EN DONDE R{SUB,1} Y R{SUB,2} SON - IGUALES O DIFERENTES Y PUEDEN SER HIDROGENO O GRUPOS ALQUILO DE CADENA LINEAL O RAMIFICADA CON 1 A 6 ATOMOS DE C, O - FORMAR JUNTO CON EL ATOMO DE N UN HETEROCICLO CON 5 O 6 ATOMOS, R{SUB,3} Y R{SUB,4} SON, IGUALES O DIFERENTES, HIDROGENO, GRUPOS ALQUILO DE CADENA LINEAL O RAMIFICADA CON 1 A 6 ATOMOS DE C, GRUPOS CICLOALQUILO CON 5 O 6 ATOMOS DE C, O EL GRUPO FENILO, Y EN DONDE R{SUB,5} PUEDE SER HIDROGENO O UN GRUPO ALQUILO DE CADENA LINEAL O RAMIFICADA CON 1 A 6 ATOMOS DE C; PARA EL TRATAMIENTO DE ENFERMEDADES DEL OIDO INTERNO.
ES96112325T 1995-08-02 1996-07-31 Empleo de derivados de adamantano para el tratamiento de tinnitus. Expired - Lifetime ES2116801T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19528388A DE19528388A1 (de) 1995-08-02 1995-08-02 Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs

Publications (1)

Publication Number Publication Date
ES2116801T3 true ES2116801T3 (es) 1998-07-16

Family

ID=7768513

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96112325T Expired - Lifetime ES2116801T3 (es) 1995-08-02 1996-07-31 Empleo de derivados de adamantano para el tratamiento de tinnitus.

Country Status (14)

Country Link
US (1) US6066652A (es)
EP (2) EP0759295B1 (es)
JP (1) JP3568039B2 (es)
KR (1) KR100393296B1 (es)
CN (1) CN1142775C (es)
AT (1) ATE163545T1 (es)
AU (1) AU719018B2 (es)
BR (1) BR9609950A (es)
DE (3) DE19528388A1 (es)
DK (1) DK0759295T3 (es)
ES (1) ES2116801T3 (es)
IL (1) IL123142A (es)
PL (1) PL324795A1 (es)
WO (1) WO1997004762A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649621B2 (en) * 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US7132406B2 (en) * 1998-02-23 2006-11-07 Sound Pharmaceuticals Incorporated Stimulation of cellular regeneration and differentiation in the inner ear
DE19807426A1 (de) * 1998-02-23 1999-10-14 Otogene Biotechnologische Fors Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs
EP1814532B1 (en) 1999-05-27 2012-01-18 George F. El Khoury Topical application of muscarinic and opioid agents for treatment of tinnitus
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
ES2292611T3 (es) * 2000-08-08 2008-03-16 Evergreen Packaging International B.V. Procedimiento para la activacion de componentes secuestradores de oxigeno durante un proceso de llenado de cajas de carton con tapa de pico.
EP1190709A1 (en) * 2000-09-21 2002-03-27 Tinnitus Forschungs- und Entwicklungs GmbH Treatment of tinnitus
EP1201234A3 (en) * 2000-09-21 2003-03-12 Tinnitus Forschungs- und Entwicklungs GmbH Treatment of diseases with adamantane derivates
EP1190711A1 (en) * 2000-09-21 2002-03-27 Tinnitus Forschungs- und Entwicklungs GmbH Treatment of diseases with adamantane derivatives
EP1325743A4 (en) 2000-10-13 2004-12-15 Chugai Pharmaceutical Co Ltd COMPOSITIONS TO IMPROVE FAT METABOLISM
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US7795468B2 (en) * 2001-01-19 2010-09-14 Chevron U.S.A. Inc. Functionalized higher diamondoids
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
EP1545551A4 (en) * 2002-09-06 2008-10-22 Durect Corp DISTRIBUTION OF MODULATORS OF THE GLUTAMAT-MEDIATED NEUROTRANSMISSION TO THE INNER EAR
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8349359B2 (en) 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060211650A1 (en) * 2004-12-16 2006-09-21 Forest Laboratories, Inc. Reducing carbohydrate derivatives of adamantane amines, and synthesis and methods of use thereof
EP1861161A4 (en) * 2005-01-24 2012-05-16 Neurosystec Corp APPARATUS AND METHOD FOR DISPENSING THERAPEUTIC AND / OR OTHER AGENTS IN THE INTERNAL EAR AND OTHER FABRICS
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
JP2008531726A (ja) * 2005-03-04 2008-08-14 ニューロシステック コーポレイション 改良されたガシクリジン製剤
KR101406456B1 (ko) * 2005-04-06 2014-06-20 아다마스 파마슈티칼스, 인코포레이티드 Ｃｎｓ 장애의 치료를 위한 방법 및 조성물
US20070021352A1 (en) * 2005-07-20 2007-01-25 Cypress Bioscience, Inc. Prevention and treatment of hearing disorders
SI1928405T1 (sl) 2005-09-28 2014-12-31 Auris Medical Ag Farmacevtski sestavki za zdravljenje motenj notranjega ušesa
US8267905B2 (en) * 2006-05-01 2012-09-18 Neurosystec Corporation Apparatus and method for delivery of therapeutic and other types of agents
US7803148B2 (en) * 2006-06-09 2010-09-28 Neurosystec Corporation Flow-induced delivery from a drug mass
WO2008011125A2 (en) * 2006-07-20 2008-01-24 Neurosystec Corporation Devices, systems and methods for ophthalmic drug delivery
CA2659330A1 (en) * 2006-07-31 2008-02-07 Neurosystec Corporation Nanoparticle drug formulations
US20080065002A1 (en) * 2006-09-07 2008-03-13 Neurosystec Corporation Catheter for Localized Drug Delivery and/or Electrical Stimulation
US20100129467A9 (en) 2007-08-31 2010-05-27 Albritton Iv Ford D Nutritional supplement
ES2596262T3 (es) * 2007-09-12 2017-01-05 Merz Pharma Gmbh & Co. Kgaa Derivados de 1-amino-alquilciclohexano para su uso en el tratamiento de tinnitus asociado con pérdida de audición
TW201010691A (en) * 2008-06-12 2010-03-16 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
US8454877B2 (en) * 2009-04-03 2013-06-04 Pelican Products, Inc. Method and apparatus for molding an article
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
US20150044200A1 (en) 2011-12-12 2015-02-12 Otolanum Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
BR112017024610A2 (pt) 2015-06-24 2018-07-31 F. Hoffmann-La Roche Ag anticorpos para receptor antitransferrina com afinidade especificada
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
RU2753390C1 (ru) 2015-10-02 2021-08-13 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела к человеческому cd20/человеческому рецептору трансферрина и способы их применения

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328251A (en) * 1965-12-30 1967-06-27 Du Pont Pharmaceutical compositions and methods utilizing 2-aminoadamantane and its derivatives
US4331686A (en) * 1981-08-28 1982-05-25 Pennwalt Corporation Treatment of otitis externa in dogs with beta-(1-adamantyl)-alpha,alpha-dimethylethylamine
ATE94384T1 (de) * 1989-04-14 1993-10-15 Merz & Co Gmbh & Co Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
DE3921062A1 (de) * 1989-06-23 1991-01-03 Lange Werner Therapie und prophylaxe von infektionen mit retroviren mit 1-adamantanamin hydrochlorid (amantadin) allein oder in kombination mit anderen antiviralen substanzen
DE4014672A1 (de) * 1990-05-08 1991-11-14 Werner E G Prof Dr Mueller Verwendung von adamantan-derivaten zur zytoprotektion von nicht-infizierten und virus-infizierten lymphozyten als auch anderen zelltypen

Also Published As

Publication number Publication date
EP0759295A1 (de) 1997-02-26
DE19528388A1 (de) 1997-02-06
KR19990036073A (ko) 1999-05-25
KR100393296B1 (ko) 2003-11-17
MX9800925A (es) 1998-10-31
DK0759295T3 (da) 1999-01-25
JP3568039B2 (ja) 2004-09-22
BR9609950A (pt) 1999-06-29
US6066652A (en) 2000-05-23
AU6788296A (en) 1997-02-26
CN1142775C (zh) 2004-03-24
IL123142A (en) 2001-10-31
EP0759295B1 (de) 1998-03-04
DE19680619D2 (de) 1998-10-29
EP0834310A1 (de) 1998-04-08
DE59600105D1 (de) 1998-04-09
CN1194581A (zh) 1998-09-30
JP2000515486A (ja) 2000-11-21
AU719018B2 (en) 2000-05-04
ATE163545T1 (de) 1998-03-15
IL123142A0 (en) 1998-09-24
WO1997004762A1 (de) 1997-02-13
PL324795A1 (en) 1998-06-22

Similar Documents

Publication Publication Date Title
ES2116801T3 (es) Empleo de derivados de adamantano para el tratamiento de tinnitus.
NZ332762A (en) Isobutylgaba and its derivatives for the treatment of pain
NO960380D0 (no) Middel til behandling av neurosykdommer
ATE153240T1 (de) Behandlung peri-menopausaler syndrome
PT768086E (pt) Tratamento de tinido utilizando agentes neuroprotectores
NO953575D0 (no) Farmasöytiske forbindelser
NO943521D0 (no) Anvendelse av et pyrrolidinacetamidderivat for fremstilling av et terapeutikum
PT655243E (pt) Derivados da melatonina para utilizacao no tratamento de disturbios do sono
DE69603667D1 (de) Indol-, Indazol- und Benzisoxazolderivate zur Behandlung von Schizophrenia
DK0604186T3 (da) HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
NO971743D0 (no) Farmasöytisk sammensetning for profylakse og behandling av type I allergiske sykdommer
ES2094545T3 (es) Derivados n-substituidos del 3-azabiciclo(3.2.0)heptano, como neurolepticos etc..
PT1068184E (pt) Derivados n-ariloxietilamina para o tratamento de depressao
ES2168119T3 (es) Derivados de quinoxalina para el tratamiento de tinnitus.
MX9306879A (es) Derivados de piperazina y composiciones farmaceuticas que los contienen,para el tratamiento de enfermedades del conocimiento.
DE69327077T2 (de) Carbamoylpyrrolidon-Derivate zur Behandlung von Depressionen und cerebrovasculären Störungen
TH18470A (th) อนุพันธ์เมลาโทนินสำหรับใช้ในการรักษาความผิดปกติของการหลับ
NO951798D0 (no) Terapeutiske midler
TH18470B (th) อนุพันธ์เมลาโทนินสำหรับใช้ในการรักษาความผิดปกติของการหลับ

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 759295

Country of ref document: ES